ABT and MDT Related Headlines
Go Back- Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
- Bernstein Shares Takeaways From the 5th Annual Diabetes Disruptor Conference
- Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'
- Piper Sandler on calls with diabetes clinicians
- Piper Sandler's Key MedTech Takeaways From ADA 2025
- Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings
